Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo®) for the treatment of adults infected with HIV-1

Assessment

The Minister of Health, Welfare and Sport (VWS) asked the National Health Care Institute to carry out a substantive assessment of whether the product Delstrigo® 100 mg/300 mg/245 mg film-coated tablet can be included in the Medicine Reimbursement System (GVS). In the letter, the Minister also asked for an assessment of Pifeltro® 100 mg film-coated tablets. Although both medicines contain doravirine, they do not have the same composition, which is why these two products are dealt with separately. This advice relates only to the assessment of Delstrigo®.

Delstrigo® is registered for the treatment of adults infected with human immunodeficiency virus 1 (HIV-1) without past or present evidence of resistance to the NNRTI-class, lamivudine or tenofovir. The dosage is 1 tablet once daily.

The advice of the National Health Care Institute

Delstrigo®, the fixed combination with doravirine/lamivudine/tenofovir disoproxil fumarate, can be included in the GVS on Appendix 1B of the Health Insurance Decree.

HIV-inhibiting medicinal products have held a special place within the GVS 

The HIV-inhibiting medicinal products have held a special place within the GVS since 2000. All antiretroviral medicinal products for the treatment of HIV infection are, in principle, eligible for inclusion on Appendix 1B of the Health Insurance Regulation. No pharmacoeconomic analysis is required for these medicinal products. This means no assessment of their interchangeability is needed.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.